
Opinion|Videos|September 30, 2024
Factors to Consider When Switching Therapies
The discussion covers when to consider transitioning to a new therapeutic option in CLL and the factors that influence the decision between dose modification and switching therapies.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- When is transitioning to a new therapeutic option considered, and what factors influence the decision between dose modification and switching therapies in chronic lymphocytic leukemia treatment?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Eli Lilly, Novo Nordisk Strike MFN Deals With Trump Administration to Lower GLP-1 Prices
2
MFN, DTC, and the Policy Pressure Cooker: Reshaping the US Drug Market
3
Oral Semaglutide Shows Promise for Weight Loss and Cardiometabolic Health
4
FDA Grants Orphan Drug Status to Immunotherapy for Acute Myeloid Leukemia Treatment
5








































































































































































































